| MeSH term | MeSH ID | Detail |
|---|---|---|
| Bacterial Infections | D001424 | 21 associated lipids |
| Pain | D010146 | 64 associated lipids |
| Lupus Erythematosus, Systemic | D008180 | 43 associated lipids |
| Stomach Diseases | D013272 | 7 associated lipids |
| Lung Diseases | D008171 | 37 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Skin Neoplasms | D012878 | 12 associated lipids |
| Colitis | D003092 | 69 associated lipids |
| Leishmaniasis, Visceral | D007898 | 13 associated lipids |
| Diabetes Mellitus, Type 1 | D003922 | 56 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Gisbert JP et al. | Helicobacter pylori eradication: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics for 1 week-a meta-analysis of efficacy. | 2000 | Aliment. Pharmacol. Ther. | pmid:10971230 |
| Beyer G et al. | Impact of moxifloxacin versus clarithromycin on normal oropharyngeal microflora. | 2000 | Eur. J. Clin. Microbiol. Infect. Dis. | pmid:10968328 |
| Heep M et al. | Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. | 2000 | Eur. J. Clin. Microbiol. Infect. Dis. | pmid:10968325 |
| Katsura Y et al. | Anti-Helicobacter pylori agents. 4. 2-(Substituted guanidino)-4-phenylthiazoles and some structurally rigid derivatives. | 2000 | J. Med. Chem. | pmid:10966750 |
| Ozkan Y et al. | Clarithromycin targeting to lung: characterization, size distribution and in vivo evaluation of the human serum albumin microspheres. | 2000 | Farmaco | pmid:10966162 |
| Castellote J and Porta F | [Combination of ranitidine and bismuth citrate plus 2 antibiotics in the eradication of Helicobacter pylori]. | 2000 | Med Clin (Barc) | pmid:10965489 |
| Scaglione F et al. | In vitro comparative dynamics of modified-release clarithromycin and of azithromycin. | 2000 Sep-Oct | Chemotherapy | pmid:10965100 |
| McCarty JM | Clarithromycin in the management of community-acquired pneumonia. | 2000 | Clin Ther | pmid:10963284 |
| Dupas JL et al. | [Acid suppression therapy is not required after one-week anti-Helicobacter pylori triple therapy for duodenal ulcer healing]. | 2000 Jun-Jul | Gastroenterol. Clin. Biol. | pmid:10962387 |
| Hatipoglu ON and Tasan Y | A comparative efficacy and safety study of clarithromycin, roxithromycin and erythromycin stearate in mild pneumonia. | 2000 | Yonsei Med. J. | pmid:10957888 |
| Fujiue Y et al. | [Results of antimicrobial susceptibilities of strains clinically isolated at 8 institutions in Hiroshima City to major oral antimicrobial drugs, mainly new quinolone drugs. Hiroshima Levofloxacin Susceptibility Surveillance Group]. | 2000 | Jpn J Antibiot | pmid:10955237 |
| Piqué JM | [Helicobacter pylori eradication in gastroduodenal ulcer: good, fine and not expensive]. | 2000 | Med Clin (Barc) | pmid:10953833 |
| Gomollón F et al. | [Cost-effectiveness analysis of 2 strategies of Helicobacter pylori eradication: results of a prospective and randomized study in primary care]. | 2000 | Med Clin (Barc) | pmid:10953829 |
| Boxenbaum H | Human in vivo competitive inhibition of P450 substrates: increased plasma concentrations as a function of hepatic extraction ratio and percent inhibition. | 1999 Sep-Dec | J Pharm Pharm Sci | pmid:10953254 |
| Mayhew BS et al. | An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. | 2000 | Drug Metab. Dispos. | pmid:10950845 |
| Katz VL et al. | Mycobacterium chelonae sepsis associated with long-term use of an intravenous catheter for treatment of hyperemesis gravidarum. A case report. | 2000 | J Reprod Med | pmid:10948471 |
| Sato K and Ebe T | [A study on the effect of combined chemotherapy on Mycobacterium avium complex pulmonary disease]. | 2000 | Kekkaku | pmid:10944891 |
| Daudén E et al. | Helicobacter pylori and idiopathic chronic urticaria. | 2000 | Int. J. Dermatol. | pmid:10944090 |
| Kamochi H et al. | Clarithromycin associated with torsades de pointes. | 1999 | Jpn. Circ. J. | pmid:10943628 |
| Shivkumar K | Images in cardiovascular medicine. Labile repolarization from "cell to bedside". | 2000 | Circulation | pmid:10942753 |
| Narita N | "Multi-effect" macrolides. | 2000 | Intern. Med. | pmid:10939528 |
| Morlet-Barla N et al. | [Severe hypoglycemia and recurrence caused by disopyramide-clarithromycin interaction]. | 2000 Jul 8-15 | Presse Med | pmid:10938688 |
| Kihara Y and Otsuki M | Interaction of gliclazide and rifampicin. | 2000 | Diabetes Care | pmid:10937528 |
| Theron AJ et al. | Investigation of the anti-inflammatory and membrane-stabilizing potential of spiramycin in vitro. | 2000 | J. Antimicrob. Chemother. | pmid:10933651 |
| Gücüyener K et al. | Methyl-prednisolone in neurologic complications of Mycoplasma pneumonia. | 2000 | Indian J Pediatr | pmid:10932970 |
| Yamashita H et al. | When can complete regression of low-grade gastric lymphoma of mucosa-associated lymphoid tissue be predicted after helicobacter pylori eradication? | 2000 | Histopathology | pmid:10931236 |
| Savarino V et al. | OAM for cure of Helicobacter pylori infection. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930908 |
| Kamada T et al. | Cetraxate, a mucosal protective agent, combined with omeprazole, amoxycillin, and clarithromycin increases the eradication rate of helicobacter pylori in smokers. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930905 |
| Kihira K et al. | Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930904 |
| Pilotto A et al. | Pantoprazole versus one-week Helicobacter pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly subjects. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930903 |
| Lai KC et al. | Ulcer-healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhage. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930902 |
| Hurenkamp GJ et al. | Equally high efficacy of 4, 7 and 10-day triple therapies to eradicate Helicobacter pylori infection in patients with ulcer disease. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930901 |
| Van Oijen AH et al. | Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930892 |
| Nagaya T et al. | A potential role of activated NF-kappa B in the pathogenesis of euthyroid sick syndrome. | 2000 | J. Clin. Invest. | pmid:10930442 |
| Hammerschlag MR | Treatment of Chlamydia pneumoniae. | 2000 | Int. J. Antimicrob. Agents | pmid:10926449 |
| Pamuk ON et al. | Are Turkish Helicobacter pylori strains gaining resistance against clarithromycin? | 2000 | Am. J. Gastroenterol. | pmid:10926000 |
| Frueh BE et al. | Mycobacterium szulgai keratitis. | 2000 | Arch. Ophthalmol. | pmid:10922211 |
| Lerner FE et al. | Clarithromycin bioequivalence study of two oral formulations in healthy human volunteers. | 2000 | Int J Clin Pharmacol Ther | pmid:10919343 |
| McCarty J et al. | Clarithromycin suspension vs penicillin V suspension in children with streptococcal pharyngitis. | 2000 Jan-Feb | Adv Ther | pmid:10915400 |
| Miwi H et al. | Comparison of the efficacy of 400mg and 800mg of clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection in a Japanese population. | 2000 | J. Gastroenterol. | pmid:10905362 |
| Moayyedi P et al. | Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Leeds HELP Study Group. | 2000 | Lancet | pmid:10905240 |
| Bortolotti M et al. | Dose-related stimulatory effect of clarithromycin on interdigestive gastroduodenal motility. | 2000 | Digestion | pmid:10899723 |
| Kato M et al. | Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. | 2000 | Antimicrob. Agents Chemother. | pmid:10898707 |
| Jordan MK et al. | Effects of fluconazole and clarithromycin on rifabutin and 25-O-desacetylrifabutin pharmacokinetics. | 2000 | Antimicrob. Agents Chemother. | pmid:10898693 |
| Jamal MA et al. | Molecular basis of clarithromycin-resistance in Mycobacterium avium intracellulare complex. | 2000 | Tuber. Lung Dis. | pmid:10897378 |
| Konno M et al. | Iron-deficiency anemia associated with Helicobacter pylori gastritis. | 2000 | J. Pediatr. Gastroenterol. Nutr. | pmid:10896071 |
| Toutous-Trellu L et al. | Three cases of cutaneous sarcoidosis: search for bacterial agent by the 16S RNA gene analysis and treatment with antibiotics. | 2000 | Dermatology (Basel) | pmid:10894973 |
| Lamouliatte H et al. | [Treatment of Helicobacter pylori infection with lansoprazole 30 mg or 60 mg combined with two antibiotics for duodenal ulcers]. | 2000 | Gastroenterol. Clin. Biol. | pmid:10891736 |
| Sung JJ et al. | Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. | 2000 | Gastroenterology | pmid:10889149 |
| Wang WH et al. | High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong. | 2000 | Aliment. Pharmacol. Ther. | pmid:10886046 |
| Savarino V et al. | The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori. | 2000 | Aliment. Pharmacol. Ther. | pmid:10886045 |
| Saito K et al. | Effect of Helicobacter pylori eradication on malignant transformation of gastric adenoma. | 2000 | Gastrointest. Endosc. | pmid:10882958 |
| Yanagihara K et al. | Combination therapy for chronic Pseudomonas aeruginosa respiratory infection associated with biofilm formation. | 2000 | J. Antimicrob. Chemother. | pmid:10882691 |
| Delchier JC | [How to eradicate Helicobacter pylori?]. | 1999 | Gastroenterol. Clin. Biol. | pmid:10880913 |
| Erel F et al. | Impact of Helicobacter pylori and Giardia lamblia infections on chronic urticaria. | 2000 Mar-Apr | J Investig Allergol Clin Immunol | pmid:10879997 |
| Suzuki K et al. | [Fibrosing alveolitis following Legionella pneumonia]. | 2000 | Nihon Kokyuki Gakkai Zasshi | pmid:10879037 |
| Maggiolo F et al. | In-vitro activity of moxifloxacin combined with other antibacterials against methicillin-resistant Staphylococcus aureus. | 2000 | J Chemother | pmid:10877512 |
| Amayasu H et al. | Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. | 2000 | Ann. Allergy Asthma Immunol. | pmid:10875487 |
| Fraser AG et al. | Helicobacter pylori treatment and antibiotic susceptibility: results of a five-year audit. | 1999 | Aust N Z J Med | pmid:10868529 |
| Mikasa K | [Study of effects and mechanisms of macrolide as biological response modifier for lung cancer treatment]. | 2000 | Jpn J Antibiot | pmid:10868303 |
| Drago L et al. | Comparative effect of thiamphenicol glycinate, thiamphenicol glycinate N-acetylcysteinate, amoxicillin plus clavulanic acid, ceftriaxone and clarithromycin on pulmonary clearance of Haemophilus influenzae in an animal model. | 2000 Jul-Aug | Chemotherapy | pmid:10859433 |
| Miltner EC and Bermudez LE | Mycobacterium avium grown in Acanthamoeba castellanii is protected from the effects of antimicrobials. | 2000 | Antimicrob. Agents Chemother. | pmid:10858369 |
| Hirschl AM et al. | In vitro activities of linezolid alone and in combination with amoxicillin, clarithromycin, and metronidazole against Helicobacter pylori. | 2000 | Antimicrob. Agents Chemother. | pmid:10858365 |
| Hammerschlag MR and Roblin PM | Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. | 2000 | Int. J. Antimicrob. Agents | pmid:10854812 |
| Nagahara A et al. | Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy. | 2000 | Helicobacter | pmid:10849057 |
| Bhasin DK et al. | Comparison of seven and fourteen days of lansoprazole, clarithromycin, and amoxicillin therapy for eradication of Helicobacter pylori: a report from India. | 2000 | Helicobacter | pmid:10849056 |
| Leiper K et al. | Open label trial of oral clarithromycin in active Crohn's disease. | 2000 | Aliment. Pharmacol. Ther. | pmid:10848665 |
| Ammon S et al. | Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori. | 2000 | Aliment. Pharmacol. Ther. | pmid:10848660 |
| Katelaris PH et al. | Randomized trial of omeprazole and metronidazole with amoxycillin or clarithromycin for Helicobacter pylori eradication, in a region of high primary metronidazole resistance: the HERO study. | 2000 | Aliment. Pharmacol. Ther. | pmid:10848659 |
| Moayyedi P et al. | The effectiveness of omeprazole, clarithromycin and tinidazole in eradicating Helicobacter pylori in a community screen and treat programme. Leeds Help Study Group. | 2000 | Aliment. Pharmacol. Ther. | pmid:10848655 |
| Zullo A et al. | A new highly effective short-term therapy schedule for Helicobacter pylori eradication. | 2000 | Aliment. Pharmacol. Ther. | pmid:10848654 |
| Baños F et al. | [Effectiveness of omeprazole, clarithromycin and amoxycillin therapy to eradicate Helicobacter pylori in patients with active peptic ulcer. Preliminary results of GENPY study]. | 2000 | Med Clin (Barc) | pmid:10846695 |
| Romero Gómez M et al. | [Usefulness of Helicobacter pylori antigen detection in stools in the diagnosis of infection and confirming eradication after treatment]. | 2000 | Med Clin (Barc) | pmid:10846675 |
| Laine L et al. | Endoscopic biopsy requirements for post-treatment diagnosis of Helicobacter pylori. | 2000 | Gastrointest. Endosc. | pmid:10840297 |
| Kaushik SP and Vu C | Helicobacter pylori eradication with lansoprazole, amoxycillin and clarithromycin: testing an ideal regimen in a multicultural south east Asian population and examining factors potentially influencing eradication. | 2000 | Aust N Z J Med | pmid:10833116 |
| Gisbert JP et al. | One-week therapy with pantoprazole versus ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication. | 2000 | Eur J Gastroenterol Hepatol | pmid:10833090 |
| Miyashita N et al. | In vitro susceptibility of 7.5-kb common plasmid-free Chlamydia trachomatis strains. | 2000 | Microbiol. Immunol. | pmid:10832970 |
| Spiegel JR et al. | Prolonged ulcerative laryngitis. | 2000 | Ear Nose Throat J | pmid:10832196 |
| Flockhart DA et al. | Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. | 2000 | J Clin Psychopharmacol | pmid:10831018 |
| Zuckerman JM | The newer macrolides: azithromycin and clarithromycin. | 2000 | Infect. Dis. Clin. North Am. | pmid:10829265 |
| Rhee CS et al. | Effects of clarithromycin on rheological properties of nasal mucus in patients with chronic sinusitis. | 2000 | Ann. Otol. Rhinol. Laryngol. | pmid:10823478 |
| Suzuki H et al. | Prognostic factors of chronic rhinosinusitis under long-term low-dose macrolide therapy. | 2000 May-Jun | ORL J. Otorhinolaryngol. Relat. Spec. | pmid:10810255 |
| Azuma T et al. | Pharmacokinetics of clarithromycin in Helicobacter pylori eradication therapy in patients with liver cirrhosis. | 2000 | Aliment. Pharmacol. Ther. | pmid:10807427 |
| Boruchoff SE et al. | The steady-state disposition of indinavir is not altered by the concomitant administration of clarithromycin. | 2000 | Clin. Pharmacol. Ther. | pmid:10801243 |
| Boyanova L et al. | Primary and combined resistance to four antimicrobial agents in Helicobacter pylori in Sofia, Bulgaria. | 2000 | J. Med. Microbiol. | pmid:10798553 |
| Vernet Vernet M et al. | [Analysis of indications and diagnosis of the gastroscopies requested by primary care physicians]. | 2000 | Aten Primaria | pmid:10795440 |
| Shimizu T et al. | Successful treatment using clarithromycin for a cutaneous lesion caused by Mycobacterium szulgai. | 2000 | Br. J. Dermatol. | pmid:10792258 |
| Calvet X et al. | A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. | 2000 | Aliment. Pharmacol. Ther. | pmid:10792124 |
| Marini RP et al. | Ranitidine bismuth citrate and clarithromycin, alone or in combination, for eradication of Helicobacter mustelae infection in ferrets. | 1999 | Am. J. Vet. Res. | pmid:10791942 |
| Waites K et al. | Use of clindamycin disks To detect macrolide resistance mediated by ermB and mefE in Streptococcus pneumoniae isolates from adults and children. | 2000 | J. Clin. Microbiol. | pmid:10790089 |
| Shibl AM et al. | Penicillin-resistant and -intermediate Streptococcus pneumoniae in Saudi Arabia. | 2000 | J Chemother | pmid:10789552 |
| Kane CL et al. | Disseminated cutaneous Mycobacterium chelonae infection. | 2000 Mar-Apr | Cancer Control | pmid:10783823 |
| Abisheganaden JA et al. | Effect of clarithromycin on experimental rhinovirus-16 colds: a randomized, double-blind, controlled trial. | 2000 | Am. J. Med. | pmid:10781777 |
| Fujimura S et al. | Clarithromycin-susceptible Helicobacter pylori with mutation in 23S rRNA gene by PCR-RFLP method. | 2000 | J. Gastroenterol. | pmid:10777165 |
| Najib MM et al. | Cost-effectiveness of sparfloxacin compared with other oral antimicrobials in outpatient treatment of community-acquired pneumonia. | 2000 | Pharmacotherapy | pmid:10772376 |
| Singer J et al. | Symptomatic and health status outcomes in the Canadian randomized MAC treatment trial (CTN010). Canadian HIV Trials Network Protocol 010 Study Group. | 2000 | Int J STD AIDS | pmid:10772083 |
| Adamsson I et al. | Microbial ecology and treatment of Helicobacter pylori infections: review. | 2000 | J Chemother | pmid:10768510 |
| Bojarski C et al. | Patients with dyspepsia benefit from eradication of Helicobacter pylori if other organic causes for dyspepsia were carefully ruled out. | 2000 | Z Gastroenterol | pmid:10768243 |
| Offman E et al. | Oral absorption of clarithromycin in acute illness and during convalescence in patients with community-acquired pneumonia. | 2000 | Chest | pmid:10767245 |
| Gasbarrini A et al. | Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus. | 2000 | Scand. J. Gastroenterol. | pmid:10766318 |